Literature DB >> 14762777

Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease.

William S Mow1, Eric A Vasiliauskas, Ying-Chao Lin, Phillip R Fleshner, Konstantinos A Papadakis, Kent D Taylor, Carol J Landers, Maria T Abreu-Martin, Jerome I Rotter, Huiying Yang, Stephan R Targan.   

Abstract

BACKGROUND & AIMS: Crohn's disease patients can be characterized by antibody responses against Crohn's disease-related bacterial sequence, Escherichia coli outer membrane porin C, Saccharomyces cerevisiae (oligomannan), and neutrophil nuclear antigens. Our aim was to determine whether expression of antibodies against Crohn's disease-related bacterial sequence and Escherichia coli outer membrane porin C is associated with distinct phenotypic manifestations.
METHODS: Sera from 303 patients were tested for antibodies to the Crohn's disease-related bacterial sequence (I2), anti-Escherichia coli outer membrane porin C, anti-Saccharomyces cerevisiae, and perinuclear antineutrophil cytoplasmic antibodies and for 3 Crohn's disease-associated variants of the NOD2 gene (R702W, G908R, and 1007fs) and compared with clinical data.
RESULTS: Patients expressing I2 were more likely to have fibrostenosing Crohn's disease (64.4% vs. 40.7%; P < 0.001) and to require small bowel surgery (62.2% vs. 37.4%; P < 0.001). Patients with anti-Escherichia coli outer membrane porin C were more likely to have internal perforating disease (50.0% vs. 30.7%; P = 0.001) and to require small bowel surgery (61.4% vs. 44.2%; P = 0.003). Anti-Crohn's disease-related bacterial sequence was independently associated with fibrostenosis (P = 0.027) and small bowel surgery (P = 0.01), whereas anti-Escherichia coli outer membrane porin C was independently associated with internal perforations (P < 0.006). Patients positive for I2, anti-Escherichia coli outer membrane porin C, and anti-Saccharomyces cerevisiae were the most likely to have undergone small bowel surgery (72.0%; odds ratio, 8.6; P < 0.001) compared with patients without reactivity (23.0%). When the presence and magnitude of antibody responses were considered, 90% of patients with small bowel disease who required surgery had high levels of I2, Escherichia coli outer membrane porin C, and oligomannan antibodies, compared with only 18.2% with low-titer responses (P < 0.001).
CONCLUSIONS: I2 and anti-Escherichia coli outer membrane porin C are associated with Crohn's disease phenotypes, and patients with the highest level of serum reactivity toward an increasing number of microbiota have the greatest frequency of strictures, internal perforations, and small bowel surgery.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14762777     DOI: 10.1053/j.gastro.2003.11.015

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  164 in total

1.  Anti-Saccharomyces cerevisiae antibodies associate with phenotypes and higher risk for surgery in Crohn's disease: a meta-analysis.

Authors:  Zhaoxia Zhang; Chen Li; Xinmei Zhao; Chaolan Lv; Qiong He; Shan Lei; Yandong Guo; Fachao Zhi
Journal:  Dig Dis Sci       Date:  2012-06-06       Impact factor: 3.199

2.  Serum antibodies and anthropometric data at diagnosis in pediatric Crohn's disease.

Authors:  Anna K Trauernicht; Steven J Steiner
Journal:  Dig Dis Sci       Date:  2011-11-11       Impact factor: 3.199

3.  Choosing Therapy on the Basis of Disease Classifications in Inflammatory Bowel Disease.

Authors:  Maria T. Abreu
Journal:  Curr Treat Options Gastroenterol       Date:  2004-06

4.  Predictors of aggressive inflammatory bowel disease.

Authors:  Andres J Yarur; Sebastian G Strobel; Amar R Deshpande; Maria T Abreu
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-10

5.  Recurrent duodenal stricture secondary to untreated Crohn's disease.

Authors:  Timothy A Plerhoples; Jeffrey A Norton
Journal:  Dig Dis Sci       Date:  2012-10       Impact factor: 3.199

Review 6.  IBD-what role do Proteobacteria play?

Authors:  Indrani Mukhopadhya; Richard Hansen; Emad M El-Omar; Georgina L Hold
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-02-21       Impact factor: 46.802

7.  Current Controversies in Crohn's Disease: A Roundtable Discussion of the BRIDGe Group.

Authors:  Miles P Sparrow; Peter M Irving; Leonard Baidoo; Brian Bressler; Adam S Cheifetz; Shane M Devlin; Laura E Harrell; Jennifer Jones; Patricia L Kozuch; Gil Y Melmed; Fernando S Velayos; Corey A Siegel
Journal:  Gastroenterol Hepatol (N Y)       Date:  2008-10

8.  Serologic and laboratory markers in prediction of the disease course in inflammatory bowel disease.

Authors:  Marla Cindy Dubinsky
Journal:  World J Gastroenterol       Date:  2010-06-07       Impact factor: 5.742

9.  The Role of Serologic and Genetic Testing in IBD: Now and Looking Ahead.

Authors:  Dermot McGovern
Journal:  Gastroenterol Hepatol (N Y)       Date:  2010-09

10.  Genetic epistasis of IL23/IL17 pathway genes in Crohn's disease.

Authors:  Dermot P B McGovern; Jerome I Rotter; Ling Mei; Talin Haritunians; Carol Landers; Carrie Derkowski; Deb Dutridge; Marla Dubinsky; Andy Ippoliti; Eric Vasiliauskas; Emebet Mengesha; Lily King; Sheila Pressman; Stephan R Targan; Kent D Taylor
Journal:  Inflamm Bowel Dis       Date:  2009-06       Impact factor: 5.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.